<DOC>
	<DOCNO>NCT01393548</DOCNO>
	<brief_summary>This multicenter clinical trial , phase III , non-inferiority , control active medicine , open , randomize , enroll 538 child , 2 12 year old , acute inflammation upper airway , characterize nasal congestion runny nose , last least 24 hour maximum 48 hour prior inclusion . The subject allocate 2 parallel group , receive medicine study , accord randomization .</brief_summary>
	<brief_title>Efficacy Safety Combination Brompheniramine Phenylephrine Symptoms Relief Rhinitis</brief_title>
	<detailed_description>This study evaluate efficacy safety experimental drug The study design evaluate efficacy safety fix combination Decongex® Plus Syrup Decongex® Plus Oral Solution ( consist brompheniramine maleate phenylephrine hydrochloride ) compare Resfenol® Oral Solution ( paracetamol , maleate chlorpheniramine phenylephrine hydrochloride ) treatment nasal congestion rhinorrhea present acute attack viral rhinitis ( common cold ) allergic . This study population consist participant sex , age 6 11 year old acute inflammatory condition upper airway , define nasal congestion runny nose , less 24 ( twenty four ) hour maximum 48 ( forty-eight ) hour prior inclusion .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Ephedrine</mesh_term>
	<mesh_term>Pseudoephedrine</mesh_term>
	<mesh_term>Brompheniramine</mesh_term>
	<criteria>1 . Patients 2 12 year old , sexes . Must responsible able understand provide ICF able allow compliance treatment protocol requirement , fulfil regular visit ; 2 . Patients symptoms acute inflammation upper airway , start 24 48 hour inclusion study protocol ; 3 . Presence runny nose classification moderate severe ( score 2 3 ) , accord responsible evaluation ; 4 . Presence nasal congestion classification moderate severe ( score 2 3 ) , accord responsible evaluation . 1 . Patients young 2 year percentile body weight and/or height less 25 ; 2 . History nasal obstruction chronic rhinosinusitis / nasal polyposis ; 3 . Oral chronic respirator history six month ; 4 . Personal history nasal surgery opinion investigator influence resistance nasal airflow ; 5 . Patients clinical history confirm ( diagnose ) asthma ; 6 . Patients medicine treatment chronic allergy ; 7 . Patients gastroesophageal reflux disease ; 8 . Presence psychiatric illness kind ; 9 . Presence mental retardation cause ; 10 . Diagnosis renal hepatic failure ; 11 . Patients genetic syndrome ; 12 . History hypersensitivity ( ) drug ( ) study excipients ; 13 . Use prohibit medicine within prescribed period V0 Inclusion Visit ( Table 1 ) ; 14 . Patients participate last 12 month , clinical trial protocols ; 15 . Patients didn´t updated vaccine book ; 16 . Relatives sponsor´s study site´s employee ; 17 . Suggestive sign bacterial infection upper airway rhinoscopy , otoscopy oroscopy ; 18 . Presence anemic/inflamed turbinate anterior rhinoscopy ; 19 . Presence septal deviation grade II III ( region nasal cavity ) / nasal polyp , condition determinant nasal obstruction ; 20 . Presence purulent mucopurulent secretion , nasal vault mal formation ( cleft lip cleave nasolabial correct ) nasal vestibule ; 21 . Current evidence clinically significant disease : hematopoietic , gastrointestinal , cardiovascular , hepatic , renal , neurological , endocrine , psychiatric , autoimmune , pulmonary , another disease block patient participation ; 22 . Any finding clinical observation ( anamnesis physical exam ) laboratory abnormality ( eg , blood glucose , blood count ) , disease ( example , liver , cardiovascular system , lung ) therapy , opinion investigator , may endanger patient interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>common cold</keyword>
	<keyword>nasal symptom</keyword>
	<keyword>child</keyword>
</DOC>